Key points from article :
Insilico, an AI drug discovery company, described its process for making an experimental drug for idiopathic pulmonary fibrosis (IPF).
Used their AI platform PandaOmics to identify a new target TRAF2- and NCK-interacting protein kinase (TNIK).
Another AI platform, Chemistry42, was then used to design a small molecule drug candidate (INS018_055) to target TNIK.
The entire process took only 18 months, significantly faster than traditional methods.
INS018_055 is currently in Phase 2 clinical trials.
Experts believe this could be a turning point for AI-driven drug discovery.
Insilico plans to license this technology to other pharmaceutical companies like Exelixis.
Research published in the journal Nature Biotechnology.
